Equivalent Glycemic Load and Insulinemic Response Elicited by 7 Low Carbohydrate Products in Heal… (NCT05870891) | Clinical Trial Compass
CompletedNot Applicable
Equivalent Glycemic Load and Insulinemic Response Elicited by 7 Low Carbohydrate Products in Healthy Adults
Canada25 participantsStarted 2023-06-15
Plain-language summary
The purpose of this study is to test the hypothesis that the equivalent glycemic load (EGL) value of portions of white bread containing 5 g available carbohydrate measured in this study is accurate and precise to within 1 gram. Additionally, the EGL of 7 low carbohydrate foods will be measured to determine their glycemic impact.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18-75 inclusive
* Willing to abstain from unusual strenuous exercise and consuming alcoholic drinks for 24 hours before study days
* Willing to refrain from smoking tobacco or marijuana for 12h before and during study visits
* Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator
* Subjects must be eligible to receive income in Canada and be covered by a health insurance plan such as OHIP
Exclusion Criteria:
* Failure to meet any one of the inclusion criteria at screening
* Pregnant or lactating individuals
* Personal history of diabetes
* Major trauma or surgical event within 3 months of screening
* The presence of any laboratory result, health condition, illness or drug use that increases risk to the subject or to others or may affect the results, as judged by the Qualified Investigator
* Unwillingness or inability to comply with experimental procedures and to follow INQUIS safety guidelines
* Known intolerance, sensitivity, or allergy to any ingredients in the study test meals. All allergens should be assumed to be a result of manufacturing practices.
* Subject is currently participating or recently (within 30 days of screening) participated in a clinical trial involving long-term exposure (greater than 24 hours) to an investigational drug, nutritional supplement or lifestyle modification